Anti cancer regimen using anti-CD47 antibody and anti-CD20 antibody

摘要

A regimen for treating CD20 + cancer, especially lymphoma, is disclosed. The regimen includes administering anti-CD20 and anti-CD47 antibodies in a number of cycles at an appropriate dosage and dosage interval.